Specimen Collection Manual and Test Catalog
LUNG CANCER (NSCLC) ROS1 (6Q22) REARRANGEMENT,FISH
Geisinger Epic Procedure Code: LAB1021 Geisinger Epic ID: 52009Lung tissue biopsy in formalin-fixed paraffin-embedded tissue block OR 5x5 mm tumor tissue in culture transport medium. 4-5 microns section on charged slide (x5)
Preferred: Lung tissue biopsy in formalin-fixed paraffin-embedded tissue block. Alternative Specimens: 5x5 mm tumor tissue in culture transport medium. 4-5 microns sections on charged slide (x5)
Lung tissue biopsy, formalin-fixed, paraffin-embedded block or charged/+ slides from formalin fixed paraffin embedded tissue. Specimen MUST be fixed in 10% neutral buffered formalin. Fixation between 6 and 48 hours is recommended.
Pathology report must accompany paraffin block or slides. Information required in this report include: Physician identification, specimen identifiers (case and block number), specimen site and type, tissue processing used (routine or microwave), type of fixative, time and duration of fixation, pathologic diagnosis. Ship at room temperature. Do not freeze. Do not reject.
Room temperature.
Specimen viability decreases during transit. Send specimen to testing lab for viability determination. Do not freeze. Do not reject.
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only.
100-300 interphase cells are microscopically analyzed for probe signal patterns indicating rearrangement of ROS1 located at 6q22. If results are not possible, the test order may be canceled and replaced with a Cytogenetics Communication.
Crizotinib, FISH, Lung Cancer (NSCLC),Non-Small Cell Lung Cancer (NSCLC),Xalkori®,ROS1 (6q22) Rearrangement, Quest test code 91836, FISH ROS1
Lung Cancer (NSCLC), ROS1 (6q22) Rearrangement, FISH - ROS1 rearrangement has been identified in 1.7% of non small-cell lung cancer (NSCLC) by using a FISH assay. Treatment with ALK/MET tyrosine kinase inhibitors such as crizotinib (Xalkori(R)) has shown early evidence of therapeutic efficacy in ROS1-rearranged NSCLC (Bergethon, et al. J Clin Oncol. 2012;30:863-870)